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We hypothesized that agonist-induced contraction correlates with the phosphocoﬁlin/coﬁlin (P-CF/CF) ratio in pulmonary artery
(PA) rings and cultured smooth muscle cells (PASMCs).PA rings were used for isometric contractions and along with PASMCs for
assay of P-CF/CF by isoelectric focusing and immunoblotting. The P-CF/CF measured 22.5% in PA and diﬀerentiated PASMCs,
but only 14.8% in undiﬀerentiated PASMCs. With comparable contraction responses in PA, endothelin-1 (100nM) and nore-
pinephrine (1μM) induced a 2-fold increase of P-CF/CF, while angiotensin II (1μM) induced none. All agonists activated Rho-
kinaseandLIMK2,andactivationwaseliminatedbyinhibitionofRho-kinase.MicrocystinLF(20nM)potentiatedtheangiotensin
II, but not the 5-hydroxytryptamine (1μM)-mediated increase of P-CF/CF. In conclusion, all tested agonists activate the Rho-
kinase-LIMK pathway and increase P-CF/CF. Angiotensin II activates PP2A and counteracts the LIMK-mediated CF phosphory-
lation. CF phosphorylation stabilizes peripheral actin structures and may contribute to the maximal contraction of PA.
Copyright © 2008 Yan-Ping Dai et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The pulmonary circulation facilitates gas exchange between
inhaled air and blood, and serves as a blood reservoir and a
ﬁlter. Smooth muscle cell layers of pulmonary arteries (PA)
play a primary role in these functions by regulating vascu-
lar myogenic tone and pulmonary blood ﬂow. The majority
of smooth muscle cells (SMCs) in healthy pulmonary blood
vessels is diﬀerentiated, and their primary functions are to
contract and relax. These functions are carried out by actin
and myosin, which provide the driving force of the contrac-
tion response [1, 2]. However, the actomyosin coupling and
production of muscle force is modulated by other proteins
associatedwiththecontractiondomainthatincludetheactin
binding proteins calponin, h-caldesmon, and tropomyosin
[3, 4]. It is also becoming increasingly clear that SMC con-
traction depends on proteins that associate with actin struc-
tures proximal to the cell membrane such as cSrc, focal ad-
hesion kinase (FAK), paxillin, integrins, HSP27, and coﬁlin.
These proteins participate in the formation of focal adhesion
complexes by mediating attachment of stress ﬁbers to the cell
membrane [5].
Coﬁlin (CF) is an actin binding protein which functions
in the cell periphery as the principal depolymerizing pro-
tein of subcortical actin complexes [6, 7]. CF localizes at the
pointed ends of actin ﬁlaments and decreases their length
by dissociating ADP-coupled actin monomers [8]. The actin
depolymerization activity of CF is regulated by pH, asso-
ciation with adaptor proteins, and interaction with phos-
phoinositides [9, 10]. However, reversible phosphorylation
is the most important mechanism: only nonphosphorylated
CF possesses actin ﬁlament-depolymerizing activity, while
Ser3-phosphorylated CF lacks such activity [11, 12]. There-
fore, the phosphorylation state of CF governs its capacity to
maintain the integrity of the subcortical actin network.
Phosphorylation of CF is mediated by two protein ki-
nase families: the testicular protein kinase (TESK) and LIM
kinase (LIMK). However, TESK is activated upon cell at-
tachment onto ﬁbronectin and transduces signals from in-
tegrin receptors to peripheral actin structures [13]. LIMK2 Advances in Pharmacological Sciences
is activated by soluble ligands and activation is mediated
by monomeric GTPases of the Rho family and subsequent
activation of the Rho-dependent protein kinases PAK and
Rho-kinase [14–16]. Rho GTPases can be activated by di-
verse agents that include contraction neurotransmitters [17],
hormones[18], mitogens and growth factors [19–22],angio-
genic agents [23], or cell stress [24–26]. Therefore, the Rho
GTPase-Rho-kinase-LIMK pathway may provide the key sig-
nal that controls the CF-mediated remodeling of the subcor-
tical actin network in response to activation of diverse cell
membrane receptors or stress factors [11, 14]. However, the
activation pattern and the role of CF for actin ﬁlament re-
modeling in contracting vascular smooth muscle is unde-
ﬁned.
The goal of this study is to evaluate how contraction ag-
onists alter the phosphorylation state of coﬁlin in freshly dis-
sectedcaninePAringsandinculturedPASMCs,andtoassess
signal transduction events involved in the coﬁlin phospho-
rylation at rest and during contraction of pulmonary artery
smooth muscle.
2. MATERIAL AND METHODS
2.1. Animaltreatmentandtissuedissection
The investigation conforms to the Guide for the Care and Use
of Laboratory Animal published by the US National Insti-
tutes of Health (NIH Publication no. 85-23, revised 1996),
and with speciﬁc protocols approved by the Animal Care
and Use Committee at the University of Nevada Reno. Ca-
nine lungs were obtained from adult mongrel dogs of either
sexeuthanizedbybarbiturateoverdose.Lungsweredissected
and second-order pulmonary artery branches were isolated,
which were then used to cut rings for isometric contraction
experiments, or to disperse and culture vascular myocytes, as
described in our previous publications [27].
2.2. DispersionofPASMCs
Second-order branches of canine PA were dissected, cleaned
from connective tissue, and placed in Ca2+-free Hank’s so-
lution, containing 125mM NaCl, 5.36mM KCl, 15.5mM
NaHCO3,0 . 3 4 m MN a 2HPO4,0 . 4 4 m MK H 2PO4,1 0 m M
glucose, 2.9mM sucrose, 10mM HEPES, pH 7.4, at 37
◦C.
Blood vessels were opened by longitudinal dissections, en-
dothelial cells were scraped with cotton swabs and smooth
muscle layers were minced and digested, and smooth muscle
c e l l sw e r ec u l t u r e da sd e s c r i b e dp r e v i o u s l y[ 27].
2.3. Isometriccontractionexperiments
Freshly dissected canine PA rings (about 2mm diameter)
were mounted in 10ml organ baths and force displace-
ments were monitored with Fort 10 isometric force trans-
ducers in a Myobath 4 system (World Precision Instruments,
Sarasota, Fla, USA). A resting force of 1g was applied to
each muscle segment. This was found to stretch tissue seg-
ments to near the optimum length for tension development.
In all experiments, tissues were initially equilibrated for 1
hour followed with at least 3 alternating 3-minute expo-
s u r e st oK C l( 3 0m m o l / L )e v e r y1 5m i n u t e si no r d e rt oe s -
tablish viability and equilibrate the tissue. Contraction ago-
nists were added to bath solutions to a ﬁnal concentration
of 1μM norepinephrine (NE), angiotensin II (AngII) or 5-
hydroxytryptamine (5-HT), 100nM endothelin-1 (ET-1), or
2U/mlthrombin.Contractionresponsesweremonitoredfor
5 minutes, followed by extensive wash. In some experiments
PA rings were incubated with Y-27632 (1μM) or microcystin
LF(MCLF,20nM)for1hourpriortoandduringtheincuba-
tion with contraction agonists. At the plateau of contraction,
tissues were snap-frozen and homogenized to extract soluble
protein.
2.4. TreatmentofculturedPASMCs
First passage PASMCs were grown to conﬂuence in complete
growthmediumM199supplementedwith10%newborncalf
serum(NCS)andthendiﬀerentiatedforthreedaysinserum-
free medium. Cells were then incubated for diﬀerent times
with 1μM NE, AngII or 5-HT, 100nM ET-1, 2U/ml throm-
bin. In some experiments, cells were preincubated for 1 hour
withY-27632(1μM)ormicrocystinLF(MCLF,20nM)prior
to incubation with contraction agonists.
2.5. Totalproteinextractionandimmunoblotting
Total protein was extracted from PA rings by glass-glass ho-
mogenization in 10 volumes of Ripa buﬀer (50mM Tris,
pH 7.4, 150mM NaCl, 5mM Na2EDTA, 0.5% (v/v) NP40,
0.5% (v/v) Triton X-100, 1mM NaF, 1μM leupeptin, and
1μM AEBSF) and sonication. Treated PASMCs were lysed
with Ripa buﬀer. Total protein concentrations were assayed
by a Micro BCA Protein Assay kit (Pierce Biotechnology,
Rockford, Ill, USA). Equal amounts of total protein were
resolved by SDS-PAGE and transferred onto nitrocellulose
membranes for 1 hour at 24V (Genie blotter, Idea Scien-
tiﬁc Company, Minneapolis, Minn, USA). The membranes
were blocked for 30 minutes with LI-COR blocking buﬀer
(LI-COR, Inc., Lincoln, Neb, USA) and probed simulta-
neously with a primary monoclonal antibody against CF
(Upstate Biotechnology, Lake Placid, NY, USA) and a pri-
mary rabbit polyclonal antibody against P-CF (Cytoskele-
ton, Denver, Colo, USA) diluted in LI-COR buﬀer. After re-
moval of primary antibodies, membranes were incubated
with two secondary antibodies: anti-rabbit, coupled to an
infrared ﬂuorescence marker with emission wavelength of
800nm (IR800, Rockland Immunochemicals, Pa, USA), and
anti-mouse, coupled to an infrared ﬂuorescence marker with
emission wavelength of 680nm (Alexa Fluor 680, Molecular
Probes, Ore, USA), diluted in LI-COR buﬀer. Double-color
ﬂuorescent images were obtained with an Odyssey scanner
(LI-COR, Inc., Lincoln, Neb, USA). Immunoreactive band
densities of P-CF were normalized to immunoreactive bands
of CF and treatment-dependent changes were expressed rel-
ative to untreated controls.Yan-Ping Dai et al. 3
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Figure 1:Assayofthephosphocoﬁlin(P-CF)contentincaninePAringsandculturedPASMCsbyIEF.TotalproteinfromfreshlydissectedPA
rings(panel(a))andundiﬀerentiatedanddiﬀerentiatedcells(panel(b));recombinantCFcontrol(rCF)wereresolvedbyIEFelectrophoresis
on gels containing 1% of each ampholyte pH 6/8 and 7/9. For CF dephosphorylation, protein extracts were incubated with calf intestinal
alkaline phosphatase (AP) prior to IEF electrophoresis. Protein was transferred onto nitrocellulose membranes and membranes were probed
with a coﬁlin antibody that recognizes both unphosphorylated (CF) and phosphocoﬁlin (P-CF). Immunoreactive bands were quantiﬁed by
densitometry, and treatment-dependent changes of the P-CF/CF ratio were presented relative to untreated controls (Ctr). Vertical strips of
gels (0.5cm wide) were cut into 1cm long segments and soaked in deionized water before assay of pH (pH bar in panel A). Panel (c): CF
expression is upregulated in proliferating PASMCs (cultured in 10% NCS), compared to diﬀerentiated cells (cultured for 4 days in 0% NCS).
2.6. Isoelectricfocusing(IEF)electrophoresis
IEF gel slabs were casted in plastic cassettes purchased from
BioRad (Hercules, Calif, USA), with gel compositions rec-
ommended by the manufacturer. The predicted isoelectric
point (pI) of canine CF is 8.07 (Acc. DR105214), therefore
equal volumes of ampholytes with pH ranges 6/8 and 7/9
were added to the gel mixture to a ﬁnal concentration of
1%.TotalproteinextractsfromPAringsorculturedPASMCs
were mixed with glycerol and ampholytes (same pH range as
in the gel composition) to ﬁnal concentrations of 40% glyc-
erol and 1% ampholytes. Samples were then loaded on IEF
gels and protein was resolved by a stepwise voltage program
(100V for 60minutes, 250V for 60minutes, and 500V for
30minutes) in 20mM NaOH as cathode buﬀer and 7mM
phosphoric acid as anode buﬀer. Vertical protein-free strips
(about 5mm wide) were excised from the edge of each gel
and divided into 1cm-long segments. Segments were then
soaked in 100μl distilled water for assay of the pH gradient
throughout the gel. Protein from the IEF gel was then trans-
ferred onto nitrocellulose in 7mM acetic acid as the trans-
fer buﬀer for 1 hour at 24V and 4◦C (Genie blotter, Idea
Scientiﬁc Company, Minneapolis, Minn, USA). Membranes
were probed with CF antibodies and immunoreactive im-
ages were developed and quantiﬁed as described in the pre-
vious section. To dephosphorylate CF, we incubated protein
extracts with calf intestinal alkaline phosphatase as recom-
mended by the manufacturer(PromegaCorp., Madison Wis,4 Advances in Pharmacological Sciences
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Figure 2: Norepinephrine-(NE) induced contraction and CF phosphorylation of PA rings were attenuated by the Rho-kinase inhibitor
Y-27632. Freshly dissected canine PA rings were incubated with 1μM NE without (panel (a)) or after 1-hour preincubation with Y-27632
(1μM panel (b)). Strips were snap-frozen at the maximal contraction amplitude and homogenized. Total protein was resolved by SDS-PAGE
and transferred onto nitrocellulose membranes. CF and P-CF were assayed by immunoblotting (panel (c)). Immunoreactive P-CF band
densities (panel (c), top inset) were normalized to immunoreactive CF bands (panel (c), bottom inset), and treatment-induced changes in
P-CF/CF ratio were expressed as percent of unstimulated controls (Ctr, bar graph). Panel (d): Schematic of signal transduction leading to
phosphorylation of coﬁlin and documented CF-mediated cell functional responses. Abbreviations: Agonist R, agonist receptor; Rho, Rho
GTPases;MLC,myosinlightchain;LIMK,LIMkinase,PPh,proteinphosphatases,MCLF,microcystinLF.Mean ±SD,(∗)P<. 05compared
to untreated controls, n = 3.
USA) prior to the IEF gel electrophoresis and immunoblot-
ting.
2.7. LIMK2immunoprecipitationandactivityassay
Total protein extracts from control and contraction agonist
treated canine PASMCs were precleared with protein A/G
agarose plus beads and then LIMK2 was immunoprecip-
itated with a goat polyclonal antibody (C-19, Santa Cruz
Biotechnology, Inc. Santa Cruz, Calif, USA). Immunopre-
cipitates were washed ﬁrst with Ripa buﬀer and then with
phosphorylation buﬀer (50mM Tris-HCl, pH 7.8, 2mM
MgCl2, 0.5mM EDTA, and 50mM NaCl). LIMK2 activity
was assayed by the phosphorylation of recombinant CF (Cy-
toskeleton, Inc., Denver, Colo, USA) in vitro in the pres-
ence of [γ-32P]ATP at 30
◦C for 15 minutes. Protein was re-
solved by SDS-PAGE (15% acrylamide), gels were stained
with Coomassie brilliant blue (CBB) and after distainingYan-Ping Dai et al. 5
were exposed onto phosphorimaging screens. CF radioac-
tive spots were visualized with a Personal Molecular Im-
ager FX (BioRad, Hercules, Calif, USA) and normalized to
the CBB-stained bands. Stimulus-speciﬁc LIMK2 activation
was expressed relative to the kinase activity of untreated
controls.
2.8. Statisticalmethods
Results are presented as the mean ± SD. The n values re-
fer to the number of parallel experiments. Student’s t-test
for paired and unpaired data, or one-way ANOVA was ap-
plied to test for diﬀerences between treatment means, as ap-
propriate. Values of P<. 05 were considered statistically
signiﬁcant.
3. RESULTS
3.1. AssessmentofCFchargeisoformsincanine
pulmonaryarterysmoothmuscle
IEF electrophoresis and immunoblotting of total protein
obtained from freshly dissected canine pulmonary arteries
and cultured PASMCs visualized two strong and one fainter
CF-like immunoreactive bands (Figure 1).One of the strong
immunoreactive bands comingrated with bacterial recom-
binant CF (rCF, Figure 1(a), lane 3) and was thus identi-
ﬁed as the unphosphorylated endogenous CF. To identify
P-CF band we dephosphorylated endogenous P-CF by in-
cubation with calf intestinal alkaline phosphatase (AP) and
then immunoblotted AP-treated samples along with un-
treated control protein extracts. Incubation with AP signif-
icantly decreased the density of the second strongest im-
munoreactive band, which was identiﬁed as the endoge-
nous P-CF (Figure 1(a), lane 2). pH measurements of ex-
tracts obtained by soaking IEF gel segments in distilled wa-
ter, revealed a linear pH gradient (Figure 1(a),p Hb a r )a n d
demonstrated that recombinant bacterial CF (unphosphory-
lated, used as control) and endogenous unphosphorylated
CF had an apparent pI of 8.2. The estimated pI of the
more acidic P-CF was 7.2 (Figure 1(a)). Our experimen-
tal CF pI (8.2) is consistent with the predicted pI of ca-
nine cardiovascular, mouse, and human CF (pI 8.07, Acc.
DR105214, NM760088 and NM005507, resp.), and with es-
timated pI values of CF and P-CF of other laboratories
[28].
To assay the fraction of the phosphorylated CF (P-CF)
compared to the total CF (i.e., the P-CF/CF ratio), we used
canine freshly dissected pulmonary artery rings and cultured
PASMCs diﬀerentiated for three days in serum-free culture
medium (Figure 1(b)). Average data from four parallel ex-
periments demonstrated that P-CF accounts for 23.2 ±1.1%
of the total CF pool in pulmonary arteries and 22.5 ± 4.4%
in diﬀerentiated PASMCs.
Cultured PASMCs have been used in previous studies of
our and other laboratories. To test how cell culturing af-
fects the fraction of P-CF, we compared the P-CF/CF ratio
of diﬀerentiated (0% NCS for three days) and in proliferat-
ing PASMCs maintained in complete culture medium (10%
NCS). Results from three parallel experiments demonstrated
that while the P-CF content changed insigniﬁcantly, the total
CF content increased in proliferating PASMCs (Figure 1(c)).
As a result, the P-CF/CF ratio decreased from 22.5 ± 4.2%
in diﬀerentiated PASMCs to 14.8 ± 4.1% in proliferating
PASMCs. These results indicate that while the total protein
content of CF is higher, the fraction of the phosphorylated
CF is relatively lower in proliferating than in diﬀerentiated
PASMCs or freshly dissected pulmonary artery rings. These
results are consistent with the notion that more dynamic
actin ﬁlament remodeling in proliferating PASMCs is asso-
ciated by higher CF activity.
3.2. ModulationofCFphosphorylationbycontraction
agonistsincaninepulmonaryarterystripsand
culturedPASMCs
Totestwhethersmoothmusclecontractionisassociatedwith
changes of the P-CF, we incubated freshly dissected pul-
monary artery strips with NE and at the maximal ampli-
tude we snap-froze tissues. Then we extracted and resolved
total protein by SDS-PAGE, and assayed CF and P-CF by si-
multaneous immunoblotting using CF and P-CF antibod-
ies, respectively. The NE-induced contraction was associ-
ated with increased phosphorylation of CF (Figures 2(a) and
2(c)). Incubation of PA rings with the Rho-kinase inhibitor
Y-27632 prior to incubation with NE attenuated both the
NE-induced contraction response (Figure 2(b)) and the NE-
mediated increase of P-CF (Figure 2(c)). The reduction of
the NE-stimulated mechanical response by Y-27632 is the
result of inhibition of the Rho-kinase-dependent activation
of myosin light chain (MLC), reported in previous studies
[17, 29]. The reduction of the P-CF content, on the other
hand, is the result of inhibition of the Rho-kinase-mediated
activation of LIMK [30]. Thus, activation of adrenergic re-
ceptors is coupled to activation of Rho GTPases, Rho-kinase,
and LIMK (Figure 2(d)).
NE is the major contraction agonist in healthy blood
vessels; however PASMCs are also exposed to other en-
dogenous contraction agonists. To test how other contrac-
tion agonists aﬀect P-CF, we incubated PA rings with ET-
1, AngII, 5HT, and thrombin and then assayed the P-
CF/CF ratio by immunoblotting. Similar to NE, these ago-
nists induced contraction responses and the maximal con-
tractions were partially inhibited by Y-27632 (not shown).
However, these agonists had distinct eﬀects on the P-CF/CF
ratio: the ET-1 and thrombin-mediated contractions were
associated with substantial about 2-fold increase of the
P-CF/CF ratio, 5-HT stimulated an increase of 1.7-fold,
while AngII caused no change of the CF phosphorylation
(Figure 3(a)).
We also assayed the P-CF/CF ratio in PASMCs cultured
in serum-free growth medium for 4 days prior to incubation
with ET-1, AngII, 5-HT, and thrombin. Overall, the pattern
of the P-CF/CF ratio in cultured PASMCs was reminiscent
of the pattern in PA rings (Figure 3(b)). Together these re-
sults indicate that increase of the CF phosphorylation is not
a common feature of all contraction agonists. The reduc-
tion of the mechanical responses by Y-27632 indicates that6 Advances in Pharmacological Sciences
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Figure 3: Contraction agonists stimulate coﬁlin phosphorylation in canine PA rings and cultured PASMCs. Freshly dissected PA rings and
diﬀerentiated PASMCs were incubated with thrombin (Thr), norepinephrine (NE), endothelin-1 (ET1), angiotensin II (AngII), and 5-
hydroxytryptamine (5-HT) for 5minutes. Total protein was extracted and resolved by SDS-PAGE, and then transferred onto nitrocellulose.
Membranes were probed simultaneously with CF and P-CF antibodies. Immunoreactive bands of P-CF were normalized to immunoreactive
bands of CF (insets) and the agonist-induced changes in the P-CF/CF ratio were presented as percentage of untreated controls (Ctr, bar
graphs). Mean ± SD, (∗) P<. 05 compared to untreated controls, n = 4.
Rho-kinase-mediatedsignalingmodulatesthecontractionto
allcontractionagents.Therefore,signaltransductionmecha-
nismsleadingtochangesofP-CFmaydissociatedownstream
of Rho-kinase, or depend on activation of alternate path-
ways that counteract Rho-kinase-LIMK-mediated phospho-
rylation of CF.
3.3. ContractionagonistsactivateLIMK2
LIMK2 is expressed in pulmonary artery smooth muscle
cells [27] and is a direct target of Rho-kinases [31]. Be-
cause the tested contraction agonists activated Rho-kinase,
it is likely that they activate also LIMK2. To test this possi-
bility, we incubated canine PASMCs with NE, ET-1, AngII,
thrombin, and 5-HT and then immunoprecipitated LIMK2
from cell total protein extracts. Kinase activity was assayed
by the phosphorylation of recombinant CF in vitro in the
presence of [γ-32P]ATP. All contraction agonists activated
LIMK2,withET-1beingthestrongest(261±52%)andAngII
being the weakest activator (125 ± 35%) at these concen-
trations (Figure 4). The activation of LIMK2 by ET-1, NE,
5-HT, and thrombin closely resembled the agonist-induced
increase of the CF phosphorylation, indicating that activa-
tionofLIMK2isdirectlycoupledtoCFphosphorylation(see
Figure 3).However,theAngII-mediatedactivationofLIMK2
(Figure 4) caused insigniﬁcant change of the P-CF fraction
(Figure 3), suggesting that in addition to the activation of
LIMK2, the phosphorylation state of CF in AngII-treated
c e l l sm a yd e p e n do no t h e rp a t h w a y sa sw e l l .
3.4. PP2AisinvolvedintheAngII-mediated
phosphorylationofcoﬁlin
The AngII-mediated increase of P-CF was insigniﬁcant com-
pared to NE, ET-1, 5-HT, and thrombin; therefore we tested
the possibility that AngII activates CF phosphatases. Since
PP2A dephosphorylates CF [12, 32], we incubated canine
PASMCs with a PP2A inhibitor, microcystin LF (MCLF,
20nM) for 1 hour prior to a 5-minute incubation with AngII
and 5-HT (positive control). Incubation with MCLF alone
causedaslightincreaseoftheP-CFcontentto132±26%(P<
.05) indicating that PP2A activity modulates the phosphory-
lation level of CF. Moreover, MCLF potentiated the AngII-
stimulated CF phosphorylation from 104±13% (AngII con-
trol, P>. 05) to 198 ± 42% (AngII + MCLF, P<. 05, n = 3)
(Figure 5(a)). In the 5-HT-treated group, incubation with
MCLF did not signiﬁcantly potentiate the 5-HT-mediated
increase of P-CF (Figure 5(b)). These results indicate that
activation of AngII receptors is associated with activation
of PP2A, which is likely to cause CF dephosphorylationYan-Ping Dai et al. 7
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Figure 4: Contraction agonists activate LIMK2 in canine PASMCs.
Canine PASMCs were incubated with thrombin (Thr), nore-
pinephrine (NE), endothelin-1 (ET1), angiotensin II (AngII), and
5-hydroxytryptamine (5-HT) for 5min. LIMK2 was immunopre-
cipitated from total protein homogenates and kinase activity was
assayed by the phosphorylation of recombinant CF in the presence
of[γ-32P]ATPinvitro.ReactionproteinwasresolvedbySDS-PAGE,
gels were stained with Coomassie brilliant blue and then exposed
on phosphorimaging screens. CF radioactive bands (top inset) were
normalizedtoproteinbands(lowerinset)andtheagonist-mediated
activation of LIMK2 was expressed as percentage of the activity of
untreated cell controls (Ctr, bar graph). Mean ± SD, (∗) P<. 05
compared to untreated controls, n = 3.
in the AngII-treated group. However, activation of PP2A
plays a minor role in the 5-HT-mediated phosphorylation of
CF.
4. DISCUSSION
This study demonstrates that exposure of pulmonary artery
smooth muscle to various contraction agonists is associated
with stimulus-speciﬁc changes of the phosphorylation state
of CF. CF functions primarily in cell subcortical areas and
modulates the remodeling of peripheral actin structures and
cellular responses to extracellular stimuli. During smooth
muscle contraction, for example, phosphorylation and inac-
tivation of CF could reduce dissociation of peripheral actin
ﬁlaments and hence stabilize stress ﬁber attachment to focal
adhesion complexes [30, 31]. Ultimately, this could facilitate
am o r ee ﬃcient pull and potentiate cell shortening and de-
velopment of maximal contraction. This scenario is consis-
tent with the increased P-CF content in freshly dissected PA
rings and in diﬀerentiated PASMCs exposed to NE, ET-1, 5-
HT, and thrombin. It is also consistent with previous studies
demonstrating that thrombin [33], 5-HT [34, 35], NE and
ET-1[34,36]activateRhoGTPasesandthenRho-kinaseand
LIMK. Surprisingly, however, the contraction response of PA
to AngII developed without a concomitant increase of the P-
CF content, although the AngII-induced contraction was as-
sociated with activation of Rho-kinase. We also conﬁrmed
that AngII, as well as ET-1, NE, thrombin, and 5-HT activate
LIMK2 in our system, thus ruling out the possibility that the
lack of change of the P-CF content is due to lack of activa-
tion of LIMK by AngII. Therefore, the phosphorylation of
CF in AngII-treated pulmonary artery appeared to depend
on other mechanisms as well.
The role of AngII in the activation of Rho GTPase has
been controversial. Sakurada et al., for example, have re-
portedlackofactivationofRhoinrabbitaorticsmoothmus-
cle [34], however, AngII activates Rho in rat renal arterioles
[37, 38]. These studies suggest that the AngII-mediated ac-
tivation of the Rho GTPase- Rho-kinase-LIMK-CF pathway
may vary among species and/or vascular beds. These diﬀer-
ences may be underlined by diﬀerences in the relative expres-
sion of the two major AngII receptor types, that is, type I
(AT1R) and type II (AT2R), or in their postreceptor mecha-
nisms.Previousstudies,forexample,havedemonstratedthat
activation of AT2R may negatively regulate RhoA and MLC
phosphorylation [39]. Other studies have shown that AT2R
is coupled to activation of the protein phosphatase PP2A
[40, 41], which is also involved in the dephosphorylation of
CF [12, 32]. Therefore, the eﬀect of AngII on the phospho-
rylation of CF in PA smooth muscle may depend on the rel-
ative expression and activation of AT1R and AT2R and re-
ﬂect the balance between the AT1R-mediated activation of
the Rho-Rho-kinase-LIMK pathway and AT2R-mediated in-
hibition of Rho-Rho-kinase-LIMK signaling and/or activa-
tionofPP2A.Ourresultsareconsistentwiththeconceptthat
AngII receptors mediate both activation of Rho-kinase and
activation of a CF phosphatase such as PP2A. Recent studies
point to slingshot as the primary CF phosphatase [42, 43],
however, the link between AngII receptors and Slingshot re-
mains undeﬁned.
With respect to the functional role of coﬁlin in contract-
ing vascular smooth muscle, our results are consistent with
the following speculations. Firstly, CF phosphorylation and
inactivation plays a minor, if any, role for the contraction re-
sponse to NE, ET-1, thrombin, and 5-HT, and particularly
to AngII. This conclusion does not exclude the possibility
that inhibition of the CF phosphorylation may decrease the
maximal contraction to NE, ET-1, thrombin, and 5-HT, or
thatinhibitionofCFphosphatasesmayincreasethemaximal
contraction to AngII. However, addressing these possibilities
will require the development of speciﬁc pharmacological ac-
tivators and inhibitors of CF kinases (i.e., LIMK and TESK)
or CF phosphatases (i.e., Slingshot) for use in whole tissue
preparations. Secondly, the P-CF content increases from a
resting level of about 23% to 42% in thrombin-treated, and
toabout50%inNEorET-1-tratedPArings.Suchaccumula-
tionofinactiveP-CFhasbeenshowntoinducetheformation
of stress ﬁbers and focal adhesions in HeLa cells [31]. Simi-
larly, an increase of the P-CF/CF ratio in PA smooth muscle
is likely to stabilize the peripheral actin network and focal
adhesions, and be beneﬁcial for the contraction response of
smooth muscle cells.8 Advances in Pharmacological Sciences
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NE(1 μM)
wash
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Figure 5: Inhibition of protein phosphatase PP2A potentiates AngII-induced phosphorylation of CF. Canine PASMCs were incubated with
microcystin LF (MCLF, 20nM) for 1 hour prior to 5minutes incubations with angiotensin II (AngII, 1mM) and 5-hydroxytryptamine (5-
HT, 1mM). Total protein was resolved by SDS-PAGE and then transferred onto nitrocellulose. Membranes were probed simultaneously with
CF and P-CF antibodies. Immunoreactive bands of P-CF (a) were normalized to immunoreactive bands of CF (b) and the agonist-induced
changes in the P-CF/CF ratio were presented as percentage of the ratio in untreated controls (Ctr, bar graphs). Mean ± SD, (∗) P<. 05
compared to untreated controls, n = 3.
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